Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > December 22, 2022
Daily News
December 22, 2022
- Chuikyo Reps in Face-Off over Medical Fees to Address Drug Supply Disruptions
December 22, 2022
- Takeda, Mitsubishi, IIF to Operate Shonan iPark under New Joint Firm
December 22, 2022
- Genmab Files Epcoritamab for Large B-Cell Lymphoma in Japan
December 22, 2022
- Product Coverage for FY2023 Price Revision “Deeply Regrettable”: FPMAJ
December 22, 2022
- Japan to Cut 310 Billion Yen in Drug Spending in FY2023 Off-Year Revision: Ministers
December 22, 2022
- Special PMP Increase to Offset 95% of Price Cuts for 150 Products: FY2023 Revision
December 22, 2022
- Padcev/Keytruda Combo Accepted for FDA Review in Bladder Cancer
December 22, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…